立体定向放射外科治疗肾细胞癌脑转移的临床结局与靶向基因组分析
单机构回顾性分析2010年1月1日至2021年3月31日接受立体定向放射外科(SRS)治疗的91例肾细胞癌(RCC)脑转移(BM)患者共212个病灶,中位随访38.8个月。SRS后12个月持久局部控制率为83%,中位颅内无进展生存期7.8个月、总生存期21个月;BM+患者PI3K通路改变(43% vs 16%,p=0.001,q=0.01)及PTEN改变(17% vs 2.7%,p=0.003,q=0.041)较BM-患者更常见。
要点
- SRS治疗RCC脑转移12个月持久局部控制率为83%。
- 中位颅内无进展生存期7.8个月,中位总生存期21个月。
- BM+患者PI3K通路改变43% vs BM-患者16%(p=0.001,q=0.01)。
核心结论
- SRS对RCC脑转移提供持久的照射野内局部控制,识别SRS后假性进展对确保恰当管理至关重要。
- PI3K通路改变在BM+患者中较BM-患者更常见,需在前瞻性研究中进一步探讨。
研究设计与样本
- 单机构回顾性分析,纳入2010年1月1日至2021年3月31日接受SRS治疗的RCC脑转移患者。
- 共91例RCC脑转移患者,接受SRS治疗212个脑转移灶。
- 对患者存活者中位随访38.8个月。
- 采用新一代测序识别BM患者中更常见的基因改变,对≥10%样本中改变的基因及临床因素进行分析。
主要发现
- 中位颅内无进展生存期为7.8个月(四分位距5.7-11),中位总生存期为21个月(四分位距16-32)。
- SRS后12个月持久局部控制率为83%。
- 3个月评估时初步满足影像学进展标准的病灶中,59%在6个月评估时会被认为代表假性进展。
- BM+患者PI3K通路改变为43% vs BM-患者16%(p=0.001,q=0.01)。
- BM+患者PTEN改变为17% vs BM-患者2.7%(p=0.003,q=0.041)。
关键数值与推荐
- BM+患者PI3K通路改变43% vs BM-患者16%(p=0.001,q=0.01)。
- BM+患者PTEN改变17% vs BM-患者2.7%(p=0.003,q=0.041)。
- SRS后12个月持久局部控制率为83%。
- 中位颅内无进展生存期7.8个月(四分位距5.7-11),中位总生存期21个月(四分位距16-32)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular profiles of renal cell carcinoma (RCC) brain metastases (BMs) are not well characterized. Effective management with locoregional therapies, including stereotactic radiosurgery (SRS), is critical as systemic therapy advancements have improved overall survival (OS). OBJECTIVE: To identify clinicogenomic features of RCC BMs treated with SRS in a large patient cohort. DESIGN, SETTING, AND PARTICIPANTS: A single-institution retrospective analysis was conducted of all RCC BM patients treated with SRS from January 1, 2010 to March 31, 2021. INTERVENTION: SRS for RCC BMs. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Next-generation sequencing was performed to identify gene alterations more prevalent in BM patients. Clinical factors and genes altered in ≥10% of samples were assessed per patient using Cox proportional hazards models and per individual BM using clustered competing risks regression with competing risk of death. RESULTS AND LIMITATIONS: Ninety-one RCC BM patients underwent SRS to 212 BMs, with a median follow-up of 38.8 mo for patients who survived. The median intracranial progression-free survival and OS were 7.8 (interquartile range [IQR] 5.7-11) and 21 (IQR 16-32) mo, respectively. Durable local control of 83% was achieved at 12 mo after SRS, and 59% of lesions initially meeting the radiographic criteria for progression at 3-mo evaluation would be considered to represent pseudoprogression at 6-mo evaluation. A comparison of genomic alterations at both the gene and the pathway level for BM+ patients compared with BM- patients revealed phosphoinositide 3-kinase (PI3K) pathway alterations to be more prevalent in BM+ patients (43% vs 16%, p = 0.001, q = 0.01), with the majority being PTEN alterations (17% vs 2.7%, p = 0.003, q = 0.041). CONCLUSIONS: To our knowledge, this is the largest study investigating genomic profiles of RCC BMs and the only such study with annotated intracranial outcomes. SRS provides durable in-field local control of BMs. Recognizing post-SRS pseudoprogression is crucial to ensure appropriate management. The incidence of PI3K pathway alterations is more prevalent in BM+ patients than in BM- patients and warrants further investigation in a prospective setting. PATIENT SUMMARY: We examined the outcomes of radiotherapy for the treatment of brain metastases in kidney cancer patients at a single large referral center. We found that radiation provides good control of brain tumors, and certain genetic mutations may be found more commonly in patients with brain metastasis.
引用
- Ma J, Del Balzo L, Walch H, et al. Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic Radiosurgery. Eur Urol Oncol. 2024. PMID: 39107179. doi:10.1016/j.euo.2024.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。